124
Participants
Start Date
November 30, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
ABT-894
6 mg BID tablets, 8 weeks of treatment
placebo
BID tablets, 8 weeks of treatment
Site Reference ID/Investigator# 7911, Sabadell, Barcelona
Site Reference ID/Investigator# 11201, Berlin
Site Reference ID/Investigator# 7229, New Hyde Park
Site Reference ID/Investigator# 6475, Granada
Site Reference ID/Investigator# 6575, Allentown
Site Reference ID/Investigator# 6618, Charlotte
Site Reference ID/Investigator# 6356, Hollywood
Site Reference ID/Investigator# 6358, Wellington
Site Reference ID/Investigator# 6615, Tampa
Site Reference ID/Investigator# 6234, Düsseldorf
Site Reference ID/Investigator# 6238, Nevers
Site Reference ID/Investigator# 6609, St Louis
Site Reference ID/Investigator# 5549, L’Aquila
Site Reference ID/Investigator# 6607, Oklahoma City
Site Reference ID/Investigator# 5554, Olomouc
Site Reference ID/Investigator# 6616, San Antonio
Site Reference ID/Investigator# 7714, Munich
Site Reference ID/Investigator# 5557, Limoges
Site Reference ID/Investigator# 9363, Corbeil-Essonnes
Site Reference ID/Investigator# 6614, Spring Valley
Site Reference ID/Investigator# 6617, Walnut Creek
Site Reference ID/Investigator# 6564, Bad Mergentheim
Site Reference ID/Investigator# 8179, San Antonio
Site Reference ID/Investigator# 5552, Hradec Králové
Site Reference ID/Investigator# 5553, Zlín
Site Reference ID/Investigator# 11202, Mainz
Site Reference ID/Investigator# 5558, Perugia
Site Reference ID/Investigator# 5555, Birmingham
Site Reference ID/Investigator# 7133, Sheffield
AbbVie (prior sponsor, Abbott)
INDUSTRY